Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CardioVascular BioTherapeutics (CVBT) has revealed results from two randomized, double-blind, placebo-controlled study, Phase IIa and Phase IIb clinical trial evaluating CVBT-141B, its biological therapy as a treatment for diabetic wounds.
Subscribe to our email newsletter
The data from CVBT’s Phase II trial suggested that CVBT’s FGF-1 biological drug showed efficacy at a level greater than has been seen in any other treatments, for patients suffering from chronic ischemic diabetic wounds.
In the Phase IIa trial, diabetic wounds treated with FGF-1 healed approximately 4.5 times faster than wounds treated with placebo/standard of care (which included debridement).
Additionally, in the Phase IIb trial, all of the diabetic wounds treated with FGF-1 achieved 100% closure within five months or less, whereas a full one-third of the placebo-treated wounds remained open at the end of the same treatment period.
CVBT CEO Daniel Montano said that CVBT-141B appears to be delivering a major treatment breakthrough for the treatment of chronic ischemic diabetic wounds.
"With this Phase I and Phase II clinical trial data, CVBT plans to request FDA approval to commence a pivotal Phase III trial for CVBT-141B. Additionally, CVBT plans to apply for ‘Fast Track Development Program’ status for CVBT-141B," Montano said.